Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 2,951 Shares

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 2,951 shares of the stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $228.95, for a total transaction of $675,631.45. Following the completion of the sale, the insider directly owned 123,499 shares of the company’s stock, valued at $28,275,096.05. This represents a 2.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Solomon Moshkevich also recently made the following trade(s):

• On Friday, December 12th, Solomon Moshkevich sold 4,692 shares of Natera stock. The stock was sold at an average price of $230.76, for a total transaction of $1,082,725.92.
• On Monday, December 1st, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $238.15, for a total transaction of $714,450.00.
• On Monday, November 3rd, Solomon Moshkevich sold 3,000 shares of Natera stock. The stock was sold at an average price of $198.60, for a total value of $595,800.00.
• On Tuesday, October 28th, Solomon Moshkevich sold 1,198 shares of Natera stock. The shares were sold at an average price of $191.46, for a total transaction of $229,369.08.
• On Monday, October 27th, Solomon Moshkevich sold 1,008 shares of Natera stock. The stock was sold at an average price of $192.32, for a total transaction of $193,858.56.
• On Tuesday, October 21st, Solomon Moshkevich sold 292 shares of Natera stock. The shares were sold at an average price of $187.95, for a total transaction of $54,881.40.

Natera Price Performance

NASDAQ:NTRA opened at $248.74 on Wednesday. The stock’s 50 day simple moving average is $224.18 and its two-hundred day simple moving average is $184.78. Natera, Inc. has a 1 year low of $125.38 and a 1 year high of $249.15. The company has a market cap of $34.41 billion, a price-to-earnings ratio of -108.62 and a beta of 1.62.

Natera (NASDAQ:NTRA) last released its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The company had revenue of $592.18 million for the quarter, compared to the consensus estimate of $514.55 million. During the same period in the prior year, the firm posted ($0.26) EPS. The business’s revenue for the quarter was up 34.7% compared to the same quarter last year. As a group, analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Investors Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in NTRA. Northwestern Mutual Wealth Management Co. lifted its position in shares of Natera by 83.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 106 shares in the last quarter. Royal Bank of Canada increased its holdings in shares of Natera by 6.8% in the first quarter. Royal Bank of Canada now owns 171,336 shares of the medical research company’s stock valued at $24,229,000 after purchasing an additional 10,895 shares during the last quarter. Advisors Asset Management Inc. boosted its stake in Natera by 10.3% during the first quarter. Advisors Asset Management Inc. now owns 8,882 shares of the medical research company’s stock worth $1,256,000 after buying an additional 826 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in Natera in the 1st quarter valued at $7,942,000. Finally, Integrated Wealth Concepts LLC increased its stake in shares of Natera by 6.6% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after acquiring an additional 96 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analysts Set New Price Targets

NTRA has been the topic of a number of research analyst reports. Guggenheim upped their target price on Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a report on Monday. Wells Fargo & Company upped their price objective on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Barclays increased their price target on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, Zacks Research raised Natera from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Sixteen research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Natera presently has an average rating of “Moderate Buy” and an average target price of $235.29.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.